Live attenuated influenza vaccine

Live attenuated influenza vaccine
Nurse administering the FluMist product
Vaccine description
TargetInfluenza
Vaccine typeAttenuated
Clinical data
Trade namesFlumist, Flumist Quadrivalent, Fluenz Tetra
AHFS/Drugs.comMonograph
License data
Routes of
administration		Intranasal
ATC code
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • none
KEGG
 NY (what is this?)  (verify)

Live attenuated influenza vaccine (LAIV) is a type of influenza vaccine in the form of a nasal spray that is recommended for the prevention of influenza.[2][7]

It is an attenuated live vaccine, unlike other influenza vaccines, which are inactivated vaccines. Live attenuated influenza vaccine is administered intranasally,[8] while inactivated vaccines are administered by intramuscular injection. Live attenuated influenza vaccine is sold under the brand names FluMist and FluMist Quadrivalent in the United States; and the brand name Fluenz Tetra in the European Union.[4][6] FluMist was first introduced in 2003 by MedImmune.[9][10][11]

In the United States, FluMist is approved for self- or caregiver-administration.[12][13] It is the first influenza vaccine that does not need to be administered by a health care provider.[12]

  1. ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  2. ^ a b "Flumist- influenza vaccine live intranasal spray". DailyMed. 6 August 2024. Retrieved 21 September 2024.
  3. ^ Cite error: The named reference FDA Flumist was invoked but never defined (see the help page).
  4. ^ a b "FluMist Quadrivalent". U.S. Food and Drug Administration (FDA). 15 November 2019. STN 125020. Archived from the original on 28 November 2019. Retrieved 28 November 2019.
  5. ^ Cite error: The named reference Fluenz EPAR was invoked but never defined (see the help page).
  6. ^ a b "Fluenz Tetra EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 28 November 2019. Retrieved 27 November 2019.
  7. ^ Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE (September 2008). "Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age". Vaccine. 26 (38): 4940–4946. doi:10.1016/j.vaccine.2008.07.013. PMID 18662737.
  8. ^ Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. (CAIV-T Comparative Efficacy Study Group) (February 2007). "Live attenuated versus inactivated influenza vaccine in infants and young children". The New England Journal of Medicine. 356 (7): 685–696. doi:10.1056/NEJMoa065368. PMID 17301299.
  9. ^ "FDA Information Regarding FluMist Quadrivalent Vaccine". U.S. Food and Drug Administration (FDA). 16 January 2018. Archived from the original on 28 November 2019. Retrieved 27 November 2019.
  10. ^ Midthun K, Masiello S (17 July 2003). "CBER Approval Letter, Influenza Virus Vaccine, Live, Intranasal (FluMist)". U.S. Food and Drug Administration (FDA). Archived from the original on 29 September 2007. Retrieved 6 July 2008.
  11. ^ "FluMist". U.S. Food and Drug Administration (FDA). Archived from the original on 22 July 2017. Retrieved 10 April 2020.
  12. ^ a b "FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration". U.S. Food and Drug Administration. 20 September 2024. Archived from the original on 20 September 2024. Retrieved 21 September 2024. This article incorporates text from this source, which is in the public domain.
  13. ^ Jewett C (20 September 2024). "Nasal Flu Vaccine Is Approved for At-Home Use". The New York Times. Retrieved 24 September 2024.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.